Skip to content

Does general anaesthesia with xenon gas improve protection of the brain when compared to general anaesthesia with a standard anaesthetic agent?

Comparison of the effects of xenon and sevoflurane anaesthesia on neurofilament light and tau protein in patients undergoing lithotripsy: a randomised trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12618000916246
Enrollment
24
Registered
2018-05-31
Start date
2019-03-02
Completion date
2019-10-31
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

In this research project we will be comparing anaesthesia with xenon to anaesthesia with our usual anaesthetic agent, sevoflurane. Xenon has been used as an anaesthetic agent for many years but it’s use is limited because it is so expensive. In order to justify its use there needs to be good evidence that it has a significant benefit. One area in which xenon appears to have benefit is in protecting the brain during anaesthesia and surgery. There is growing evidence that having an anaesthetic and surgery can cause some problems with how the brain functions. This is of particular concern in infants and older people. This study is considering if there is evidence that xenon may be more protective of the brain than the usual anaesthetic. For the study, patients having a minor surgical procedure will have anaesthetic with either xenon or sevoflurane. We will take blood tests from both sets of patients. The blood tests will look for evidence of any harm to the brain cells of the patients to identify if one anaesthetic is better than the other.

Interventions

General anaesthesia with xenon gas. Xenon gas will be used as the sole hypnotic agent to provide general anaesthesia for participants undergoing lithotripsy. It will be administered by the inhalational route at an inspired fraction of 60% for the duration of the anaesthetic (about 45minutes) by the anaesthetist. It's use will be in conjunction with an opiod infusion (remifentanil) and other standard anaesthetic care.

Sponsors

St. Vincent's Hospital Melbourne
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients' undergoing lithotripsy at St. Vincent's Hospital, Melbourne. Patients' living within 30minutes travel time of St. Vincent's Hospital.

Exclusion criteria

Exclusion criteria include: High risk of PONV (Apfel score 3 or greater) Severe respiratory disease (unable to tolerate inspired oxygen fraction less than 35%) Contraindication to airway management with laryngeal mask airway Contraindication to anaesthesia with a volatile agent Pre-existing neurodegenerative condition

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 14, 2026